In protein studies, CD24, which is associated with tumor metastasis, and Galectin-1 expression, which is associated with immune response and tumor progression, were studied in GC patients, giving particular attention to staining intensity and clinicopathologic variables; the researchers concluded that these proteins were independent prognostic indicators of poor survival (though not specifically associated with recurrence) and could be useful as therapeutic targets [18]. The gene discussed is CD24; the disease is neoplasm.